Pricing Log in Create free account
Saturday 17 October 2026 Export AYTU’s income statement to Excel — free account

Aytu BioPharma, Inc.

AYTU Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.

2.04 0.03 +1.49%
Market cap
$21.8M
P/E
0.0×
Fwd P/E
−9.2×
Dividend yield
—
F-score
3/9
Altman Z
−4.04
Beneish M
−3.48
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 19.16%

Capital & Financial Ratios $m

Market Cap 21.84
Revenue 57.57
Net Income (14.25)
Free Cash Flow 3.24
Net Debt (9.28)
Current Ratio 1.13
Debt/Equity 0.48 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (9.18) (negative: loss-making)
P/S ratio 0.44
P/B ratio 0.71
Past 5Y EPS Growth —
This Y EPS Growth 46.26% (at or above 15%: strong)
Next Y EPS Growth 143.32% (at or above 15%: strong)
Next Y revenue growth 17.96% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.3×, against a ten-year median of 0.2×; over the ten years it ranged from −5.2× in 2016 to 33.4× in 2017.
P/S against its own 10 years 44.75%
10-year low 10-year high
P/B against its own 10 years 62.18%
10-year low 10-year high
EV/Sales against its own 10 years 41.03%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 23 20 31 26
Receivables 29 24 31 23
Inventory 12 12 11 7
Other — — — —
71 62 79 62
2023 2024 2025 2026
Payables 13 10 11 11
ST’ Debt 2 4 11 8
Other 7 9 3 0
69 62 63 55

Compound Annual Growth %

10y 5y 3y
Sales 36.51% (2.59%) (18.77%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 13.34% (23.83%) (3.59%)

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 14 15 12 16 58
’25 17 16 18 15 66
’24 18 19 14 15 65
’23 28 26 23 31 107
’22 22 23 24 27 97
’21 14 15 13 23 66
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (1) 4 (4) 4 3
’25 (1) 3 (6) 3 (2)
’24 0 0 0 (1) (1)
’23 (9) (2) (3) 9 (5)
’22 (4) (9) (9) (7) (29)
’21 (8) (3) (9) (6) (26)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (1) 4 (4) 4 3
’25 (1) 3 (7) 3 (1)
’24 0 0 0 (1) (2)
’23 (9) (2) (3) 9 (5)
’22 (4) (9) (9) (7) (29)
’21 (8) (3) (9) (9) (28)
Fiscal quarters ending in the months shown.

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 0.10 (1.05) (0.53) 0.00 (1.16)
’25 — (0.26) 0.21 (2.92) (2.16)
’24 (1.48) (0.04) (0.52) (0.82) (2.86)
’23 (0.28) (2.15) (1.93) (0.59) (5.11)
’22 (21.80) (8.80) (35.80) (9.80) (75.00)
’21 (8.00) (14.40) (28.20) (20.04) (69.60)
Fiscal quarters ending in the months shown.
value withheld pending a data check

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 8,200.00 136.00 130.00 68.00 26.40 3.00 1.38 1.30 0.95 1.89

Analyst estimates 2027–2029

Powerpack
High 100,800.00 17,040.00 522.00 598.00 235.20 31.80 4.40 3.45 2.82 3.07
People
People Employees 63 57 53 75 175 164 150 102 83 76
Revenue/emp, $m 0.05 0.06 0.14 0.37 0.38 0.59 0.72 0.64 0.80 0.76
Income, $m
Income, $m Revenue 3 4 7 28 66 97 107 65 66 58
Gross margin, % 56.00 43.98 69.92 70.03 44.49 54.08 62.04 75.26 69.04 63.95
EBT (23) (10) (27) (14) (58) (109) (17) (10) (14) (14)
EBT margin, % (698.67) (278.35) (370.63) (49.29) (88.42) (112.64) (15.88) (15.92) (20.71) (24.72)
Net income (23) (10) (27) (14) (58) (109) (17) (16) (14) (14)
Depreciation 5 3 3 6 22 85 9 7 5 4
Per share, $
Per share, $ Revenue 1,400.70 1,109.12 187.70 122.27 78.38 65.76 32.16 11.77 10.57 4.67
Earnings (9,659.72) (3,062.00) (696.00) (60.28) (69.60) (75.00) (5.11) (2.86) (2.16) (1.16)
Cash flow (6,012.91) (4,830.39) (354.65) (125.55) (31.01) (19.61) (1.54) (0.25) (0.31) 0.27
Capex (48.52) (143.85) (14.35) (25.88) (2.80) 0.00 0.00 (0.06) 0.07 0.00
Free cash flow (6,061.43) (4,974.24) (369.01) (151.43) (33.80) (19.61) (1.54) (0.31) (0.24) 0.26
Book value 1,739.04 4,068.03 181.74 420.42 164.28 30.14 11.78 5.00 3.02 2.86
Shares, m 0 0 0 0 1 1 3 6 6 12
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 33.70 0.94 2.05 2.32 1.28 0.21 0.05 0.24 0.21 0.46
P/B 27.14 0.26 2.11 0.68 0.61 0.46 0.14 0.57 0.72 0.75
EV/Sales 33.43 (1.00) 1.20 1.10 0.90 0.20 (0.01) 0.17 0.07 0.30
EV/FCF (7.72) 0.22 (0.61) (0.76) (1.47) (0.45) 0.07 (0.97) (3.04) 5.32
Cash, $m
Cash, $m Operating cash flow (14) (16) (14) (28) (26) (29) (5) (1) (2) 3
Capex 0 0 (1) (6) (2) — — 0 0 0
Free cash flow (14) (16) (14) (34) (28) (29) (5) (2) (1) 3
Balance, $m
Balance, $m Working capital (1) 6 10 47 (4) (5) 2 0 16 7
Total debt — — — 14 25 18 16 15 22 17
Net debt (1) (7) (11) (34) (25) (1) (7) (5) (9) (9)
Shareholders’ equity 4 13 7 95 138 44 39 28 19 35
Returns, %
Returns, % ROA (114.43) (56.51) (97.28) (14.49) (27.83) (53.95) (12.44) (12.45) (11.20) (12.44)
ROIC (402.85) (195.07) 0.00 (21.59) (32.72) (159.24) (32.58) (4.35) (49.77) (19.99)
ROE (319.60) (116.94) (264.55) (26.68) (50.12) (119.62) (40.76) (47.24) (58.10) (52.55)
Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

Aytu BioPharma, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IXHL Incannex Healthcare Inc. $36.1M — (loss-making) — (loss-making) −92.31% (below 0%: shrinking) n/m +327.73% (above 0%: growing) 100.00% 0.00% Compare
RMTI Rockwell Medical, Inc. $32.2M — (loss-making) — (loss-making) +10.63% (above 0%: growing) n/m −12.92% (below 0%: shrinking) 18.24% (5.97%) Compare
CPHI China Pharma Holdings, Inc. $31.3M — (loss-making) — (loss-making) −7.56% (below 0%: shrinking) n/m −113.57% (below 0%: shrinking) 8.82% (150.99%) Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc. $26.5M 0.2× — — n/m +82.01% (above 0%: growing) 0.00% 0.00% Compare
TXMD TherapeuticsMD, Inc. $22.3M — (loss-making) 18.9× −8.72% (below 0%: shrinking) −80.00% (below 0%: shrinking) +104.46% (above 0%: growing) 100.00% (93.90%) Compare
AYTU Aytu BioPharma, Inc. $21.8M — (loss-making) — (loss-making) +6.42% (above 0%: growing) n/m +57.72% (above 0%: growing) 64.63% (4.82%)
UPC Universe Pharmaceuticals INC $20.9M — (loss-making) 4.1× −23.98% (below 0%: shrinking) −110.15% (below 0%: shrinking) −84.99% (below 0%: shrinking) 32.57% 0.00% Compare
BGXXQ Bright Green Corporation $13.9M — (loss-making) — — n/m −1.46% (below 0%: shrinking) 0.00% 0.00% Compare
BFRI Biofrontera Inc. $12.6M — (loss-making) — (loss-making) +32.92% (above 0%: growing) n/m +45.57% (above 0%: growing) 79.92% (4.37%) Compare
Median of peers $24.4M — — −8.14% — +22.06% 25.41% (2.18%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Aytu BioPharma, Inc. (AYTU) key facts

  • Concern: Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.
  • Aytu BioPharma, Inc. (AYTU) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, AYTU traded at $2.04, a market capitalization of $21.8 million.
  • Return on equity was −52.6% and debt-to-equity 0.48.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.04 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.

Aytu BioPharma, Inc. (AYTU) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/AYTU · Data as of Oct 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com